Hanyang Med Rev.  2014 Feb;34(1):15-19. 10.7599/hmr.2014.34.1.15.

Lung Cancer Screening

• Won YW

• KMID: 2168308
• DOI: http://doi.org/10.7599/hmr.2014.34.1.15

Abstract

Lung cancer is the leading cause of cancer-related mortality worldwide, including in Korea. Although various treatment modalities have been developed, the prognosis of patients with lung cancer is still very unfavorable. Most patients with lung cancer are diagnosed at an advanced stage, and palliative care remains the only therapeutic option for these patients. Accordingly, early detection of lung cancer may lead to a decrease in lung cancer-related mortality. Therefore, considerable interest has been generated in the development of screening tools to detect lung cancer at an early stage. Although chest radiography and sputum cytological evaluation have been used to screen patients for lung cancer, the sensitivity and specificity of these procedures are not adequate. Recently, low-dose computed tomography (LDCT) has emerged as a promising screening technique, and several trials have demonstrated its benefit in the high-risk population. One such well-designed and well-conducted trial, the National Lung Screening Trial (NLST), showed a 20% reduction in lung cancer-related mortality. Based on the results of NLST and other trials, screening for lung cancer using LDCT is recommended in asymptomatic patients who are at a high risk for lung cancer, with regard to age and smoking history. The present report is a comprehensive review of available evidence on the benefits and risks of lung cancer screening and summarizes some recommendations.

Keyword

Lung Neoplasms; Early Detection of Cancer; Computed Tomography, X-Ray

MeSH Terms

Early Detection of Cancer
Humans
Korea
Lung Neoplasms*
Lung*
Mass Screening*
Mortality
Palliative Care
Prognosis
Radiography
Risk Assessment
Sensitivity and Specificity
Smoke
Smoking
Sputum
Thorax
Tomography, X-Ray Computed
Smoke

Reference

1. Jung KW, Won YJ, Kong HJ, Oh CM, Shin A, Lee JS. Survival of korean adult cancer patients by stage at diagnosis, 2006-2010: national cancer registry study. Cancer Res Treat. 2013; 45:162–171.

2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations)[Internet]. Bethesda: National Cancer Institute;2009. cited 2013 Nov 2. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/.

3. National Lung Screening Trial Research Team. Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013; 368:1980–1991.

4. National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365:395–409.

5. Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009; 180:445–453.

6. Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, et al. The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. J Thorac Oncol. 2009; 4:608–614.

7. Pastorino U, Rossi M, Rosato V, Marchiano A, Sverzellati N, Morosi C, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012; 21:308–315.

8. Lopes Pegna A, Picozzi G, Mascalchi M, Maria Carozzi F, Carrozzi L, Comin C, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer. 2009; 64:34–40.

9. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2004; 140:740–753.

10. Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst. 2006; 98:748–756.

11. Hocking WG, Hu P, Oken MM, Winslow SD, Kvale PA, Prorok PC, et al. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst. 2010; 102:722–731.

12. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011; 306:1865–1873.

13. Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax. 2012; 67:296–301.

14. Byrne MM, Weissfeld J, Roberts MS. Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening. Med Decis Making. 2008; 28:917–925.

15. van den Bergh KA, Essink-Bot ML, Borsboom GJ, Scholten ET, van Klaveren RJ, de Koning HJ. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J. 2011; 38:154–161.

16. International Early Lung Cancer Action Program Investigators. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006; 355:1763–1771.

17. Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ, et al. Screening for lung cancer. Cochrane Database Syst Rev. 2013; 6:CD001991.

18. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132:234S–242S.

19. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009; 136:260–271.

20. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer. 2004; 45:Suppl 2. S3–S9.

21. Ostroff JS, Buckshee N, Mancuso CA, Yankelevitz DF, Henschke CI. Smoking cessation following CT screening for early detection of lung cancer. Prev Med. 2001; 33:613–621.

22. Ashraf H, Tønnesen P, Holst Pedersen J, Dirksen A, Thorsen H, Døssing M. Effect of CT screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial (DLCST). Thorax. 2009; 64:388–392.

23. Townsend CO, Clark MM, Jett JR, Patten CA, Schroeder DR, Nirelli LM, et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer. 2005; 103:2154–2162.

24. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012; 307:2418–2429.

25. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143:e78S–e92S.